



# report

## UNDERSTANDING MERS-CoV AT THE ANIMAL-HUMAN INTERFACE

Technical meeting  
21-22 January 2016  
Rome, Italy



# UNDERSTANDING MERS-CoV AT THE ANIMAL-HUMAN INTERFACE

---

Technical meeting  
21-22 January 2016  
Rome, Italy

### Recommended Citation

**FAO.** 2016. *Understanding MERS-CoV at the Animal-Human Interface. Summary report of the technical meeting – Rome, Italy. 21-22 January 2016.* FAO Animal Production and Health Report. No. 11. Rome, Italy.

The designations employed and the presentation of material in this information product do not imply the expression of any opinion whatsoever on the part of the Food and Agriculture Organization of the United Nations (FAO) concerning the legal or development status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The mention of specific companies or products of manufacturers, whether or not these have been patented, does not imply that these have been endorsed or recommended by FAO in preference to others of a similar nature that are not mentioned.

The views expressed in this information product are those of the author(s) and do not necessarily reflect the views or policies of FAO.

ISBN 978-92-5-109242-2

© FAO, 2016

FAO encourages the use, reproduction and dissemination of material in this information product. Except where otherwise indicated, material may be copied, downloaded and printed for private study, research and teaching purposes, or for use in non-commercial products or services, provided that appropriate acknowledgement of FAO as the source and copyright holder is given and that FAO's endorsement of users' views, products or services is not implied in any way.

All requests for translation and adaptation rights, and for resale and other commercial use rights should be made via [www.fao.org/contact-us/licence-request](http://www.fao.org/contact-us/licence-request) or addressed to [copyright@fao.org](mailto:copyright@fao.org).

FAO information products are available on the FAO website ([www.fao.org/publications](http://www.fao.org/publications)) and can be purchased through [publications-sales@fao.org](mailto:publications-sales@fao.org).

---

# Table of contents

<i>Acknowledgements</i>	<i>iv</i>
<i>Abbreviations &amp; Acronyms</i>	<i>v</i>
<b>INTRODUCTION</b>	<b>1</b>
BACKGROUND	1
MEETING OBJECTIVES	2
<b>KNOWLEDGE GAPS</b>	<b>3</b>
EPIDEMIOLOGY AND RISK FACTORS	3
LABORATORY DIAGNOSTICS	4
VALUE CHAIN AND BEHAVIOURAL STUDIES	5
<b>ADDRESSING NEEDS AND KNOWLEDGE GAPS</b>	<b>6</b>
COORDINATION	6
EPIDEMIOLOGY	6
LABORATORY DIAGNOSTICS	6
VALUE CHAIN AND BEHAVIOURAL STUDIES	6
<b>ACTIVITIES UNDERTAKEN BY PARTICIPATING PARTNERS</b>	<b>7</b>
<b>ACTION POINTS</b>	<b>8</b>
ANNEX 1	
<b>AGENDA</b>	<b>9</b>
ANNEX 2	
<b>LIST OF PARTICIPANTS</b>	<b>13</b>

---

## Acknowledgments

This meeting was made possible through support provided by the Office of Health, Infectious Diseases, and Nutrition in the Bureau for Global Health, U.S. Agency for International Development, under the terms of Grant No. GHA-G-00-06-00001. The opinions expressed in this meeting report are those of the authors and do not necessarily reflect the views of the U.S. Agency for International Development.

---

## Abbreviations & Acronyms

<b>CIRAD</b>	Agricultural Research Institute for Development, France
<b>CoV</b>	Coronavirus
<b>ECTAD</b>	Emergency Centre for Transboundary Animal Diseases, FAO
<b>ELISA</b>	Enzyme-Linked Immunosorbent Assay
<b>EMC</b>	Erasmus Medical Centre, the Netherlands
<b>EPT</b>	Emerging Pandemic Threat
<b>FAO</b>	Food and Agriculture Organization of the United Nations
<b>HKU</b>	University of Hong Kong
<b>HQ</b>	Headquarters
<b>ICPALD</b>	IGAD Centre for Pastoral Areas and Livestock Development, Kenya
<b>IGAD</b>	Intergovernmental Authority on Development, Republic of Djibouti
<b>KEMRI</b>	Kenya Medical Research Institute
<b>KSA</b>	Kingdom of Saudi Arabia
<b>MoA</b>	Ministry of Agriculture
<b>MoH</b>	Ministry of Health
<b>MERS</b>	Middle East Respiratory Syndrome
<b>NRC</b>	National Research Centre, Egypt
<b>OIE</b>	World Organisation for Animal Health
<b>PCR</b>	Polymerase Chain Reaction
<b>ppNT</b>	Spike Pseudoparticle Neutralization Test
<b>RNA</b>	Ribonucleic Acid
<b>RT-PCR</b>	Reverse Transcription Polymerase Chain Reaction
<b>SAR</b>	Special Administrative Region
<b>SOP</b>	Standard Operating Procedure
<b>TWG</b>	Technical Working Group
<b>USAID</b>	United States Agency for International Development
<b>VI</b>	Virus Isolation
<b>WHO</b>	World Health Organization





---

# Introduction

The Technical Meeting on understanding Middle East Respiratory Syndrome Coronavirus (MERS-CoV) at the human-animal interface was convened by the Food and Agriculture Organization of the United Nations (FAO) to determine the current status of scientific knowledge on MERS-CoV and identify major gaps that require further studies, in order to better understand the disease dynamics at the interface between humans and animals, and to develop practical approaches to control and minimize the impact of this virus. The meeting also aimed at fostering collaboration and partnerships between institutions and organizations working on MERS-CoV at the human-animal interface. It was held in Rome from 21-22 January 2016, and was attended by 64 participants from Egypt, France, Germany, Hong Kong Special Administrative Region (SAR), Israel, Jordan, Kingdom of Saudi Arabia, The Netherlands, Qatar, United Arab Emirates, the United Kingdom and the United States, and from EcoHealth Alliance, Metabiota, International Medical Corps, the World Organisation for Animal Health (OIE), the International Atomic Energy Agency (IAEA), the Intergovernmental Authority on Development (IGAD), the International Livestock Research Institute (ILRI), the European Food Safety Authority (EFSA) and FAO. This report provides the key objectives for the meeting and summarizes major outputs that include the gaps and needs identified, and the main recommendations made by the meeting participants.

## BACKGROUND

Middle East respiratory syndrome coronavirus (MERS-CoV) can cause severe pneumonia in humans and is considered an emerging global public health threat. The disease was first detected in Saudi Arabia in 2012, and as of 3 February 2016, the WHO has been notified of 1 638 laboratory-confirmed human cases, including 587 fatalities. MERS-CoV has also been isolated from dromedary camels in several countries in the Near East and East Africa and antibodies to MERS-CoV have also been identified in very high proportions of camels in a number of countries across the Horn of Africa, North Africa and in the Near East.

Evidence suggests that primary human cases might have been exposed to the virus through contact with an animal host, and several studies have shown dromedary camels to be a source of human infection. Molecular similarities between other  $\beta$ -CoVs identified in bats and MERS-CoV isolated from camels and human patients point to the possibility of a bat reservoir. Critical gaps remain in our knowledge of many aspects of the epidemiology, ecology, and pathogenesis of MERS-CoV.

A number of research groups are currently investigating various aspects of MERS-CoV, and significant scientific information has been published during the past three years. FAO is embarking on a field programme to investigate MERS-CoV along the animal value chains in the Horn of Africa, North Africa and the Near East to better understand the disease dynamics at the animal-human interface. In this regard, FAO convened a technical meeting to determine the extent of

current scientific knowledge, identify the major study gaps, and develop practical and realistic approaches to minimize the risk of transmission to humans and reduce the adverse impacts of this virus.

**MEETING OBJECTIVES**

1. Share information on ongoing studies on the role of livestock and wildlife in the epidemiology of MERS-CoV.
2. Identify and prioritize knowledge gaps in disease dynamics at the human-wildlife-domestic animal interface.
3. Peer-review scientific and technical approaches on MERS-CoV at the human-animal interface, including the dynamics of viral emergence and evolution, surveillance design, diagnostics, and risk factors along animal value chains.
4. Analyse complementarities and synergies between programmes and projects implemented by various partners, and explore opportunities for collaboration and partnerships.

---

# Knowledge gaps

## EPIDEMIOLOGY AND RISK FACTORS

Antibody kinetics and immunity in camels

- Antibody kinetics in camels are unknown.
- Mode of protective immune response and duration of immunity are not fully elucidated.
- Whether re-infection of camels results in virus shedding, and if re-exposure leads to more robust immunity.

## Shedding patterns

- Viral replication is mainly restricted to the (upper) respiratory tract of camels; however, RNA has also been found in camel milk. The source of viral RNA in milk is unknown (haematogenous or contamination from suckling calves), and the risk of transmission from this and other sources has not been established.
- Although evidence suggests that live virus cannot be found in other bodily secretions, this should be further investigated, especially in the light of the consumption of camel urine in some countries.

## Surveillance

- Antibodies to MERS-CoV have been found to be highly prevalent in camel populations in many countries but knowledge of the geographical distribution of seropositive camels and other animals is not complete in parts of Africa and central Asia.
- Details of viral circulation in camels is largely unknown, including risk factors for transmission, such as production systems, herd size and management, seasonality and camel-level risk factors such as age, sex, immunosuppression, and co-infection.
- The naturally infected host range has not been fully explored.
- Origin of the virus is still unknown.

## Case definitions and regulatory issues

- Case definition for reporting MERS-CoV in animals has to be redefined as it is clear that not all polymerase chain reaction (PCR) positive animals are necessarily shedding infectious viruses.
- Risk communication is difficult in view of the fact that the risk of a PCR positive animal in terms of onwards animal transmission and human exposure is difficult to determine.
- The trade and regulatory implications of PCR positive animals have not been explored. For example:
  - how positive animals found during active surveillance are reported;
  - what are the quarantine recommendations for PCR positive animals;
  - what are the differences between farm level and cross-border implications of positive animals;

- What is the implication of PCR positive animals in different epidemiological (routine investigations, investigation around human cases, etc.) and production contexts (farms animals, trade animals, transhumant, racing, etc...).

### **Epidemiology of MERS-CoV in humans**

- To date, there are no reports of any acute human MERS-CoV cases in Africa, and yet a high level of seroprevalence is observed in camel populations, while one survey has shown a low level of seroprevalence in human populations.
- The reasons for the lack of reported human cases in Africa is unknown. The possible reasons identified were: missed/under-reported cases, host susceptibility, genetic differences of the virus, asymptomatic population, differences in human behaviour and healthcare systems.

### **LABORATORY DIAGNOSTICS**

#### **Serological tools**

- Commercial Enzyme-Linked Immunosorbent Assays (ELISA) are available for camel and human diagnosis. However, sensitivity and specificity of the assays have to be assessed more accurately.
- ELISA for multispecies testing is not available. Control sera for proper test validation are needed.
- Development and validation of a rapid test for camels and/or other animal species.
- Alternative confirmatory tests that do not require virus culture are needed. Only few laboratories are able to carry out tissue culture-based tests, due to the need to use BSL3 facilities. An existing test, based on the spike pseudoparticle neutralization test (ppNT), could be validated, and a confirmatory ELISA or Western blot test developed.

#### **Testing algorithms**

- Testing algorithms and Standard Operating Procedures (SOPs) are not available.
- OIE is currently processing certification for a newly developed rapid test. However, the introduction of this test in the testing algorithm needs to be evaluated.

#### **Molecular tests and molecular epidemiology**

- Many different PCR protocols are used. It is important to find out if all protocols are adapted to the circulating strains.
- Few sample types (sera, tissue, etc.) from different species (human, wildlife, domestic animals) exist for further molecular studies.
- Field samples often lack the quality necessary for sequencing.
- Molecular markers of virulence or potential for zoonotic transmission are not well known.

#### **Pathogenesis and experimental infections**

- The relation between pathogenesis and the PCR and/or serological results is not well understood.

- The circulating viruses are not well characterized genetically. Experimental infections with various strains are needed for phenotype determination.

### **Camel vaccines**

- Novel camel vaccines and modalities for effective vaccination (preventing MERS-CoV transmission), need to be further investigated.
- Where and how often should vaccines be targeted for effective intervention? (e.g. at what age, which camel populations, how frequently, is a booster needed, and how often will it have to be applied?) At what age would they be useful? Which protocol should be used and will they be culturally acceptable? Which animal population should be targeted?
- The issues surrounding a camel vaccine for public health should be explored: How to make it acceptable to camel owners, who pays for the vaccine, etc... (is the objective of vaccination only to protect public health)? Can MERS-CoV be combined with other vaccines (Rabies)? Yes, according to the Erasmus group.

### **VALUE CHAIN AND BEHAVIOUR STUDIES**

The camel sector is generally neglected compared to other livestock sectors, in terms of governance, regulations, and professional associations. This has led to a lack of readily accessible data on camel value chains. Economic drivers, as well as the supply and demand of camels, camel products, and camel feed are all little known.

#### **Production Systems**

- There is a lack of accurate numbers on overall camel populations and within each camel sector (dairy, racing, meat, etc...).
- Characterization of the production systems including intensive/extensive raising, herd sizes, other species raised, and seasonality is needed.
- Regional differences in camel raising and production systems are unknown.

#### **Trade**

- The camel sector is largely unregulated. It is therefore difficult to access the organization and structure of the value chain, and quantify camel movements in formal trade. Furthermore, informal trade is common but extremely difficult to quantify or estimate.
- There is no formal system of traceability or camel identification.

#### **Human behaviour and culture**

- Risky behaviours for disease transmission are not fully characterized, such as those activities specific to different camel sectors (racing, milking, slaughter, etc...).
- Gender roles and responsibilities in the different camel sectors and regional differences are poorly described or little known.
- The impact of culture, values and social status on camel value chains is not well known, such as transhumance routes and trade and religious or cultural festivals.
- Disease knowledge and risk perceptions among key populations have not been explored.

---

# Addressing needs and knowledge gaps

Conclusions were summarized and specific action points highlighted.

## **COORDINATION**

- Strengthen NATIONAL multisectoral/One Health platforms for MERS-CoV at the human-animal interface for information sharing, surveillance and joint outbreak investigations.
- Improve and expand INTERNATIONAL collaboration and platforms under the FAO/OIE/WHO tripartite in liaison with other global and regional partners to share knowledge, data, biological material, etc.
- Identify and disseminate methodologies/approaches that are culturally sensitive, build trust and encourage cooperation of local communities for the conduct of field activities.

## **EPIDEMIOLOGY**

- Conduct additional research to identify environmental and other ecological risk factors and geographic distribution.
- Conduct additional research to identify human behaviours that affect transmission.
- Update case definitions for animals and herds based on recent research findings.
- Develop guidelines for joint outbreak animal/human investigations.

## **LABORATORY DIAGNOSTICS**

- Develop testing algorithms and SOPs for field sampling and testing of MERS-CoV across species and countries.
- Conduct infection experiments to understand pathogenesis and immunity in different animal species.
- Conduct molecular studies for further virus characterization.
- Conduct Bayesian studies to evaluate and compare the performance of diagnostic tests.
- Create a virtual and physical biobank as a shared resource for specimens and standards.

## **VALUE CHAIN AND BEHAVIOURAL STUDIES**

- Identify critical control and intervention points along livestock value and supply chains to inform surveillance, policy, and risk management.
- Identify appropriate behaviour change options to reduce spillover and zoonotic disease transmission risk.
- Formulate risk communication messages and strategies regarding PCR-positive animals.

---

## Activities undertaken by participating partners

- Kingdom of Saudi Arabia (KSA), Ministry of Agriculture (MoA) and Ministry of Health (MoH): Longitudinal study in camels and in-contact humans, wild animal species testing in areas with human cases.
- Israel: camel serology (60 percent seroprevalence).
- ILRI and local partners such as Kenya Medical Research Institute (KEMRI), Kenya Veterinary Services, Kenya Wildlife Services, CIRAD, PREDICT-2 and Jordan Veterinary Services: virus prevalence studies (PCR and virus isolation - VI), livestock and wildlife serology, longitudinal studies in select camel herds.
- PREDICT-2 (Metabiota, EcoHealth Alliance, UC Davis): biological surveillance in wildlife, humans and domestic animals, diagnostic capacity development.
- CIRAD and Hong Kong University (HKU): Longitudinal study, camel sampling at abattoirs and farms, with human and bat sampling, virus characterization, transmission modelling, studies on 5 000 camels in Burkina Faso, Morocco, Sudan, Kazakhstan (herd management, size, etc.).
- MoA of KSA and Erasmus Medical Centre (EMC): vaccine field trials in female camels and studies of the effects on offspring.
- IGAD Centre for Pastoral Areas and Livestock Development (ICPALD) in collaboration with AU-IBAR and FAO (Emergency Centre for Transboundary Animal Diseases - ECTAD): Regional stakeholders workshop held in October 2015 with the objectives to create awareness on MERS-CoV and develop a roadmap for enhancing surveillance, improving diagnostic capacities, furthering research and enhancing coordination. The IGAD region is a major camel producing and exporting area. As a result of the workshop, a technical working group (TWG) has been established to oversee and coordinate MERS-CoV activities in the region, and mobilize resources.
- Egypt National Research Centre (NRC) and FAO (ECTAD): A cross sectional study in camels and other livestock species showed that seroprevalence in camels is 73 percent. A longitudinal study is planned.

---

## Action points

- FAO to consult with EPT2 Preparedness and Response (P&R) to assist the creation/strengthening of national One Health platforms and reinforce networks by running simulation exercises for different scenarios, etc.
- FAO to continue to provide opportunities for international scientific and field discussions/meetings (physical and virtual) to fill in knowledge gaps, develop guidance documents, share information, and standardize approaches.
- FAO to involve local research institutions and organizations in EPT-2 activities.
- FAO to facilitate policy dialogue (for different issues/levels).
- FAO to coordinate development and refinement of laboratory tests.
- FAO to create an international scientific network of expertise for MERS-CoV together with the OIE and in close consultation with WHO for public health issues.
- FAO to foster collaboration and partnerships with and between research institutions and local organizations.
- Study to be conducted on defining camel farming systems in East Africa and the Gulf countries, comparing patterns and characterizing risky human behaviour.
- Use of harmonized methodologies for field studies in order to facilitate comparison of results.
- FAO to support Regional Technical Working group on MERS-CoV such as in the IGAD region /Greater Horn of Africa.



---

# Annex 1

## Agenda

### AGENDA

## Understanding **MERS-CoV** at the **animal-human interface**

*Technical Meeting*

Rome, Italy • 21-22 January 2016



Food and Agriculture Organization  
of the United Nations

21 January

## Thursday

- 
- 08:30-09:00 Morning coffee and registration
- 09:00-09:30 Welcome, introductions and expectations
- 09:30-10:15 Scientific overview presentations:
- Epidemiology and risk factors (15 min.)
  - Laboratory diagnosis (15 min.)
  - Supply chains and behavioural studies (15 min.)
- 10:15-10:45 Coffee break
- 10:45-11:15 Plenary discussion
- 11:15-12:35 Break up into groups to discuss knowledge gaps, by thematic area as follows:
- Epidemiology and risk factors
  - Laboratory diagnosis
  - Supply chains and behavioural studies
- 12:35-13:45 Lunch
- 13:45-14:00 Collect results from group discussion
- 14:00-14:30 Plenary debriefing from group discussions (15 min. each)
- 14:30-15:00 Q&A, wrap up of knowledge gaps, plenary discussion, agreement on final statements
- 15:00-15:20 Mapping of ongoing and planned activities of participating institutions
- 15:20-15:30 Plenary session
- 15:30-16:00 Coffee, networking + review/completion of mapping exercise
- 16:20-17:20 Q&A and open discussion on opportunities for collaboration:
- Field surveillance
  - Behavioural studies
  - Capacity building, training
  - Test development and validation
  - Laboratory research
  - Other
- 17:20-18:00 Wrap-up
- 18:30-20:00 Poster session and aperitivo

22 January

Friday

- 09:00-09:15 **Recap of activities from day 1 and moving forward**
- 09:15-10:45 **Presentation of One Health implementation approach under Emerging Pandemic Threats Programme Phase 2 (EPT-2), by thematic area as follows:**
- **Surveillance and risk factors**  
(20 min. ppt + 10 min. discussion)
  - **Laboratory diagnosis**  
(20 min. ppt + 10 min. discussion)
  - **Supply chains and behavioural studies**  
(20 min. ppt + 10 min. discussion)
- 10:45-11:15 **Coffee Break**
- 11:15-12:15 **Facilitated discussion on cross-cutting collaboration:**
- Stakeholder participation
  - Information sharing
  - Communication: awareness raising, disseminating information, and risk communication
  - Capacity development
- 12:15-12:45 **Implementation approach wrap-up**
- 12:45-13:45 **Lunch**
- 13:45-14:30 **Coffee over topic discussions**
- 14:30-16:00 **Collaboration building and way forward (3 pillars: surveillance and risk factors, laboratory diagnosis, supply chains and behavioural studies):**
- Technical
  - Institutional
  - Stakeholder Level
- 16:00-16:00 **Coffee Break**
- 16:30-17:00 **Recommendations**
- 17:00 **Closure**



This meeting was made possible through financial support provided by the United States Agency for International Development (USAID).



---

## Annex 2

### List of participants



**Abu Dhabi Food Control Authority  
(ADFCA) – UAE**  
Salama Al Muhairi  
Director  
Salama.almuhairi@adfca.ae

**Centers for Disease Control and  
Prevention (CDC) – USA**  
Frederick J. Angulo  
Associate Director for Science –  
Global Health Protection Division  
FAngulo@cdc.gov

Casey Barton  
Director, One Health Office  
dlx9@cdc.gov

Sean Shadomy  
CDC Secondment to FAO  
auf4@cdc.gov

**Centre de coopération internationale  
en recherche agronomique pour le  
développement (CIRAD) – France**  
Veronique Chevalier  
Deputy Director – AGIRs Unit  
veronique.chevalier@cirad.fr

**Hong Kong University**  
Malik Peiris  
Professor, Virologist  
malik@hku.hk

**Intergovernmental Authority  
on Development (IGAD) Centre  
for Pastoral Areas & Livestock  
Development**  
Ameha Sebsibe  
Head, Livestock  
ameha.sebsibe@igad.int

**EcoHealth Alliance – USA**  
Billy Karesh  
karesh@ecohealthalliance.org

Jonathan Epstein  
Associate Vice President  
epstein@ecohealthalliance.org

**Erasmus University – the  
Netherlands**  
Bart Haagmans  
Scientist  
b.haagmans@erasmusmc.nl

**Hachaklait – Israel**

Michael van Straten  
Veterinary Epidemiologist  
vanstraten@hachaklait.co.il

**International Atomic Energy Agency  
(IAEA) – Austria**

Hermann Unger  
Technical Officer  
H.Unger@iaea.org

**International Livestock Research  
Institute (ILRI) – Kenya**

Joerg Jores  
Scientist  
j.jores@cgiar.org

**International Medical Corps – USA**

David Tarantino  
Senior Physician  
dtarantino@  
InternationalMedicalCorps.org

**Jordan University of Science and  
Technology (JUST) – Jordan**

Ehab Abu-Basha  
Dean and Professor  
abubasha@just.edu.jo

**Metabiota – USA**

Kimberly Dodd  
Scientist  
kdodd@metabiota.com

Matthew Lebreton  
Technical Advisor  
mlebreton@metabiota.com

Damien Joly  
Director, Epidemiology  
djoly@metabiota.com

**Ministry of Agriculture – Kingdom  
of Saudi Arabia**

Faisal Bayoumi  
faisalbayoumi@yahoo.com

**Ministry of Environment and  
Water – UAE**

Zaidoun Saleh Hijazeen  
Scientist  
kalanzi80@yahoo.com

**National Institutes of Health – USA**

Neeltje van Doremalen  
Visiting Postdoctoral Fellow  
neeltje.vandoremalen@nih.hhs.gov

**National Research Centre – Egypt**

Mohamed Ali  
Professor  
mohamedahmedali2004@yahoo.com

**Pasteur Institute – France**

Jean Claude Manuguerra  
Research Director  
jean-claude.manuguerra@pasteur.fr

**Royal Veterinary College – U.K.**

Imadidden Musallam  
PhD Student  
imusallam@rvc.ac.uk

**Supreme Council of Health – Qatar**

Elmoubasher Abu baker Abd Farag  
Director  
eabdfarag@sch.gov.qa

**United States Department of  
Agriculture (USDA) – USA**

Cheikh Fall  
Agricultural Specialist  
Cheikh.s.Fall@aphis.usda.gov

**United States Agency for  
International Development (USAID)  
– USA**

Andrew Clements  
Scientific Advisor  
aclements@usaid.gov

**University of Bonn – Germany**

Christian Drosten  
Director, Institute of Virology  
drosten@virology-bonn.de

**World Health Organization**

Yolanda Bayugo  
Technical Officer  
bayugo@who.int

**World Organisation for Animal Health (OIE) – France**

Gounalan Pavade  
Chargé de mission  
g.pavade@oie.int

**Individual Experts**

Mario Younan  
Camel Expert  
marioyounan@gmail.com

Scott Naysmith  
Anthropologist  
scottnaysmith@gmail.com

Jeff Gilbert  
Epidemiologist  
Dr.Jeffrey.Gilbert@gmail.com

Ziad Memish  
Senior Consultant  
zmemish@yahoo.com

**Food and Agriculture Organization (FAO), National – Egypt**

Yilma Makonnen  
ECTAD Team Leader  
Yilma.Makonnen@fao.org

**Food and Agriculture Organization (FAO), Regional – Africa, Asia and Near East**

Charles Bebay  
ECTAD Manager, West and Central Africa  
Charles.Bebay@fao.org

Bouna Diop  
ECTAD Manager, East Africa  
Bouna.Diop@fao.org

Scott Newman  
Senior Technical Coordinator,  
Viet Nam  
Scott.Newman@fao.org

Nacif Rihani  
Livestock Development Officer, UAE  
Nacif.Rihani@fao.org

Markos Tibbo  
Livestock Officer, Egypt  
Markos.Tibbo@fao.org

**Food and Agriculture Organization (FAO), Headquarters – Italy**

Juan Lubroth  
Chief, Animal Health Service  
Juan.Lubroth@fao.org

Subhash Morzaria  
Coordinator, EPT-2  
Subhash.Morzaria@fao.org

Eran Raizman  
Senior Animal Health Officer  
Head of EMPRES-Animal Health  
Eran.Raizman@fao.org

Felix Njeumi  
Animal Health Officer  
Disease Management  
Felix.Njeumi@fao.org

Julio Pinto  
Animal Health Officer  
Disease Intelligence and Information Systems  
Julio.Pinto@fao.org

Silvia Kreindel  
Veterinary Medical Officer  
Risk Assessment  
Silvia.Kreindel@fao.org

Astrid Tripodi  
Animal Health Officer  
Value Chains  
Astrid.Tripodi@fao.org

Sophie von Dobschuetz  
Veterinary Epidemiologist  
Surveillance Coordinator  
Sophie.VonDobschuetz@fao.org

Gwenaelle Dauphin  
Animal Health Officer,  
Laboratory Coordinator  
Gwenaelle.Dauphin@fao.org

Ian Sprouse  
EMPRES Volunteer  
Ian.Sprouse@fao.org

Guillaume Belot  
Veterinary Epidemiologist  
Guillaume.Belot@fao.org

Claudia Pittiglio  
Ecologist  
Claudia.Pittiglio@fao.org

Emma Gardner  
Veterinary Epidemiologist  
Emma.Gardner@fao.org

Henk Jan Ormel  
Senior Advisor to the Chief Veterinary  
Officer  
HendrikJan.Ormel@fao.org

Ahmed El-Idrissi  
Senior Animal Health Officer  
Ahmed.ElIdrissi@fao.org

Raffaele Mattioli  
Senior Officer  
Parasitic Diseases and Disease Ecology  
Raffaele.Mattioli@fao.org

Lidewij Wiersma  
Laboratory Specialist  
Lidewij.Wiersma@fao.org

Angelique Angot  
Laboratory Specialist  
Angelique.Angot@fao.org

Martina Escher  
Veterinary Epidemiologist  
Martina.Escher@fao.org

Anne-Maud Courtois  
Consultant  
AnneMaud.Courtois@fao.org

Baukje Andela  
EMPRES Volunteer  
Baukje.Andela@fao.org

Barbara Tornimbene  
Veterinary Epidemiologist  
Barbara.Tornimbene@fao.org

Alejandro Acosta  
Livestock Policy Officer  
Alejandro.Acosta@fao.org

Mona Chaya  
Senior Coordinator,  
Food Chain Crisis Management  
Framework  
Mona.Chaya@fao.org





ONLINE PUBLICATION SERIES  
**FAO ANIMAL PRODUCTION AND HEALTH REPORTS**

1. Impact of animal nutrition on animal welfare – Expert Consultation, 26–30 September 2011, FAO Headquarters, Rome, Italy. 2012 (E)  
<http://www.fao.org/3/a-i3148e.pdf>
2. FAO's support to the One Health regional approach – Towards integrated and effective animal health–food safety surveillance capacity development in Eastern Africa. Report of the Workshop, Entebbe, Uganda, 23–24 January 2013. 2013 (E)  
<http://www.fao.org/3/a-i3391e.pdf>
3. Characterization and value addition to local breeds and their products in the Near East and North Africa – Regional Workshop, Rabat, Morocco, 19–21 November 2012. 2014 (E, Ar)  
<http://www.fao.org/3/a-i3622e.pdf>  
<http://www.fao.org/3/a-i3622a.pdf>
4. The Global Platform for African Swine Fever and other important diseases of swine – Rome, Italy, 5-7 November 2013. 2014 (E)  
<http://www.fao.org/3/a-i3739e.pdf>
5. The role, impact and welfare of working (traction and transport) animals – Report of the FAO – The Brooke Expert Meeting, FAO Headquarters, Rome, 13<sup>th</sup> – 17<sup>th</sup> June 2011. 2014 (E)  
<http://www.fao.org/3/a-i3381e.pdf>
6. Dog population management – Report of the FAO/WSPA/IZSAM Expert Meeting, Banna, Italy, 14-19 March 2011. 2014 (E)  
<http://www.fao.org/3/a-i4081e.pdf>
7. Towards a concept of Sustainable Animal Diets – Report based on the collated results of a survey of stakeholder views. 2014 (E)  
<http://www.fao.org/3/a-i4146e.pdf>
8. Regional workshop on brucellosis control in Central Asia and Eastern Europe. 2015 (E, R)  
<http://www.fao.org/3/a-i4387e.pdf>
9. The last hurdles towards Rift Valley fever control. 2015 (E)  
<http://www.fao.org/3/a-i4466e.pdf>
10. Understanding Ebola Virus at the Animal-Human Interface. 2016 (E)  
<http://www.fao.org/3/a-i5670e.pdf>
11. Understanding MERS-CoV at the Animal-Human Interface. 2016 (E)  
<http://www.fao.org/3/a-i5682e.pdf>

Availability: May 2016

E - English  
Ar - Arabic  
R - Russian  
\*\* In preparation



Find more publications at  
<http://www.fao.org/ag/againfo/resources/en/publications.html>



ISBN 978-92-5-109242-2



9 7 8 9 2 5 1 0 9 2 4 2 2

I5682E/1/05.16